A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors

NCT01130623 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

NIH

Sponsor class

Conditions

Sarcoma
Neuroblastoma
Wilms Tumor
Osteosarcoma
Brain Tumor

Interventions

DRUG: Pazopanib (GW786034)

Sponsor

National Cancer Institute (NCI)